Trial reportBlood2011
Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand.
Trial report in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.Clinical and translational science · 2023Pooled it
- CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome.Clinical immunology (Orlando, Fla.) · 2012Trial
- CXCL9 and CXCL10 support the exacerbated humoral response in recovered COVID-19 patients who developed acute respiratory distress syndrome by promoting plasma cell differentiation, whereas CXCL9 also induces CD40L and CXCR3 upregulation on T helper cells.Frontiers in immunology · 2025Article
- CD40 Expression by B Cells Is Required for Optimal Immunity to Murine Pneumocystis Infection.The Journal of infectious diseases · 2024Article
- Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling.ACS applied bio materials · 2021Article
- The Importance of Primary Immune Deficiency Registries: The United States Immunodeficiency Network Registry.Immunology and allergy clinics of North America · 2020Review
- X-linked hyper-IgM syndrome complicated with interstitial pneumonia and liver injury: a new mutation locus in the CD40LG gene.Immunologic research · 2019Article
- CD40 ligand deficiency causes functional defects of peripheral neutrophils that are improved by exogenous IFN-γ.The Journal of allergy and clinical immunology · 2018Article
- Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.Innate immunity · 2018Review
- Periodontal and other oral manifestations of immunodeficiency diseases.Oral diseases · 2017Review
- Immunosilencing a highly immunogenic protein trimerization domain.The Journal of biological chemistry · 2015Article
- ICON: the early diagnosis of congenital immunodeficiencies.Journal of clinical immunology · 2014Review
- Recent advances in transplantation for primary immune deficiency diseases: a comprehensive review.Clinical reviews in allergy & immunology · 2014Review
- The hyper IgM syndromes.Clinical reviews in allergy & immunology · 2014Review
- Biomarkers for understanding Ebola virus disease.Biomarkers in medicine · 2014Article
- Primary antibody deficiencies.Nature reviews. Immunology · 2013Review
- Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.International reviews of immunology · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 1 country.
Funding
Abstract
X-linked hyper IgM syndrome (XHM) is a combined immune deficiency disorder caused by genetic alterations in CD40 ligand. The purpose of this study was to investigate the safety and efficacy of recombinant CD40 ligand (rCD40L) in the treatment of the disease. Three children were administered rCD40L subcutaneously 3 times per week at 0.03 mg/kg for 22 weeks, and after a 12-week drug-free interval, the dose was increased to 0.05 mg/kg for an additional 22 weeks of treatment. Although specific antibody responses to T cell-dependent antigens was lacking, administration of rCD40 resulted in acquisition of the capacity to mount cutaneous delayed type hypersensitivity reactions that disappeared during the drug-free interval as well as the postbiologic follow-up period. With rCD40L treatment, patient T cells developed a new capacity to respond to T-cell mitogens with synthesis of IFN-γ and TNF-α. Intracellular cytokine staining studies showed that both CD4(+) and CD8(+) T cells participated in this response. Finally, CD40L therapy was associated with changes in lymph node size and architecture based on comparison of biopsies taken before and after therapy. This clinical study showed that rCD40L is capable of improving T cell-immune function in patients with XHM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.